Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Madrigal Pharmaceuticals Adds John C. Reed, M.D., Ph.D., to Board of Directors

Neutral Impact 3 of 5 leadership Written later

Madrigal Pharmaceuticals expanded its Board from eight to nine members on August 11, 2026, and elected John C. Reed, M.D., Ph.D., to fill the new seat. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson, and his board appointment is a governance change with no financial results reported in the filing.

Key points

  • Board expanded from eight to nine members; Reed elected effective August 11, 2026 as a Class II director, term expiring at the 2027 annual meeting.
  • Reed receives a $50,000 annual cash retainer plus $10,000 annually for Science and Technology Committee service.
  • Initial equity grant valued at $675,000, split 50% stock options and 50% restricted stock units under the 2026 Stock Plan.

The filing

CompanyMADRIGAL PHARMACEUTICALS, INC. (MDGL)
Form8-K, current report
Filed with the SECAug 12, 2026, 8:18 AM ET
Accession number0001628280-26-055962

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.